Abstract
For the treatment of Parkinson′s disease, the second most common neurodegenerative disorder, requires a combination of levodopa with a peripheral decarboxylase inhibitor, such as carbidopa which provides a symptomatic relief to patients. Reaction of carbidopa with cis-[Cr(C2O4)2(H2O)2]– has been carried out in aqueous medium over the range 35 ≤ t ≤ 50 ºC, 4.0 ≤ pH ≤ 6.0 , 3.75 × 10-3 mol dm-3 ≤ [carbidopa] ≤ 9.38 × 10-3 mol dm-3, I (KNO3) = 0.1 mol dm-3. There is outersphere association between cis-[Cr(C2O4)2(H2O)2]– and conjugate base of carbidopa followed by first chelation. The characterization of the product was performed by using NMR and infrared spectroscopies. The product showed better antiparkinsonian activity than the combination of levodopa and carbidopa
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
